JP2011152137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011152137A5 JP2011152137A5 JP2011045589A JP2011045589A JP2011152137A5 JP 2011152137 A5 JP2011152137 A5 JP 2011152137A5 JP 2011045589 A JP2011045589 A JP 2011045589A JP 2011045589 A JP2011045589 A JP 2011045589A JP 2011152137 A5 JP2011152137 A5 JP 2011152137A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- hpv45
- protein
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims 2
- 241001138401 Kluyveromyces lactis Species 0.000 claims 2
- 241000235650 Kluyveromyces marxianus Species 0.000 claims 2
- 241000235058 Komagataella pastoris Species 0.000 claims 2
- 241000320412 Ogataea angusta Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50681203P | 2003-09-29 | 2003-09-29 | |
| US60/506,812 | 2003-09-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528190A Division JP5451960B2 (ja) | 2003-09-29 | 2004-09-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129350A Division JP2014221052A (ja) | 2003-09-29 | 2014-06-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011152137A JP2011152137A (ja) | 2011-08-11 |
| JP2011152137A5 true JP2011152137A5 (OSRAM) | 2013-04-04 |
Family
ID=34421558
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528190A Expired - Lifetime JP5451960B2 (ja) | 2003-09-29 | 2004-09-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
| JP2011045589A Pending JP2011152137A (ja) | 2003-09-29 | 2011-03-02 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
| JP2014129350A Pending JP2014221052A (ja) | 2003-09-29 | 2014-06-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
| JP2016019712A Pending JP2016136947A (ja) | 2003-09-29 | 2016-02-04 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528190A Expired - Lifetime JP5451960B2 (ja) | 2003-09-29 | 2004-09-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129350A Pending JP2014221052A (ja) | 2003-09-29 | 2014-06-24 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
| JP2016019712A Pending JP2016136947A (ja) | 2003-09-29 | 2016-02-04 | 酵母におけるｈｐｖ４５ｌ１の最適化された発現 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7250170B2 (OSRAM) |
| EP (1) | EP1673106B1 (OSRAM) |
| JP (4) | JP5451960B2 (OSRAM) |
| KR (1) | KR101165278B1 (OSRAM) |
| CN (1) | CN1859923B (OSRAM) |
| AR (2) | AR045804A1 (OSRAM) |
| AT (1) | ATE435029T1 (OSRAM) |
| AU (1) | AU2004277934B2 (OSRAM) |
| BE (1) | BE2015C072I2 (OSRAM) |
| BR (1) | BRPI0414845B8 (OSRAM) |
| CA (1) | CA2539168C (OSRAM) |
| CY (2) | CY1110525T1 (OSRAM) |
| DE (1) | DE602004021828D1 (OSRAM) |
| DK (1) | DK1673106T3 (OSRAM) |
| ES (1) | ES2327530T3 (OSRAM) |
| FR (1) | FR15C0083I2 (OSRAM) |
| HU (1) | HUS1500063I1 (OSRAM) |
| IL (1) | IL174458A (OSRAM) |
| IS (1) | IS2694B (OSRAM) |
| LT (2) | LTC1673106I2 (OSRAM) |
| LU (1) | LU92902I2 (OSRAM) |
| MX (1) | MXPA06003457A (OSRAM) |
| MY (1) | MY140664A (OSRAM) |
| NL (1) | NL300776I2 (OSRAM) |
| NO (3) | NO339932B1 (OSRAM) |
| NZ (1) | NZ545834A (OSRAM) |
| PL (1) | PL1673106T3 (OSRAM) |
| PT (1) | PT1673106E (OSRAM) |
| RU (1) | RU2360001C2 (OSRAM) |
| SI (1) | SI1673106T1 (OSRAM) |
| TW (1) | TWI350853B (OSRAM) |
| WO (1) | WO2005032586A1 (OSRAM) |
| ZA (1) | ZA200601961B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| CA2560487C (en) | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| EP1877086A2 (en) * | 2005-04-26 | 2008-01-16 | GlaxoSmithKline Biologicals SA | Vaccine |
| EP2059262B1 (en) * | 2006-08-28 | 2013-08-21 | Sungkyunkwan University Foundation for Corporate Collaboration | A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein |
| CA2679720A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| MY162658A (en) * | 2007-11-23 | 2017-06-30 | Shanghai Zerun Biotechnology Co Ltd | Genes encoding major capsid protein l1 of human papilloma virus and use of the same |
| CN102215861B (zh) | 2009-06-19 | 2014-10-08 | 艾金株式会社 | 宫颈癌疫苗 |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| JP6001064B2 (ja) | 2011-06-15 | 2016-10-05 | チュンアン ユニバーシティー インダストリー アカデミック コアポレイション ファウンデイション | ヒトパピローマウイルスｌ１タンパク質の生産収率を向上させる方法 |
| JP6050811B2 (ja) | 2011-06-24 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法 |
| CN103215302B (zh) * | 2012-01-21 | 2019-01-15 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv18 l1蛋白的方法 |
| CN108624614A (zh) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
| CN110484554B (zh) * | 2013-04-26 | 2024-04-16 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
| CN110295190A (zh) * | 2013-05-17 | 2019-10-01 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 |
| CN104513826B (zh) * | 2013-09-29 | 2020-10-20 | 上海泽润生物科技有限公司 | 人乳头瘤病毒基因,及载体,菌株,表达方法 |
| EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| AR101840A1 (es) * | 2014-09-11 | 2017-01-18 | Cadila Healthcare Ltd | Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene |
| CN106282278B (zh) * | 2015-06-29 | 2021-06-08 | 广东东阳光药业有限公司 | 一种人乳头瘤病毒l1蛋白的发酵方法 |
| CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750050B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒45亚型蛋白表达 |
| JOP20220187A1 (ar) | 2020-02-14 | 2023-01-30 | Merck Sharp And Dohme Llc | لقاح فيروس الورم الحليمي البشري (hpv) |
| CN112680462B (zh) * | 2020-12-29 | 2022-02-22 | 上海博唯生物科技有限公司 | 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
| CN118019547A (zh) | 2021-08-19 | 2024-05-10 | 默沙东有限责任公司 | 热稳定脂质纳米粒子及其使用方法 |
| US20240408188A1 (en) | 2023-06-09 | 2024-12-12 | Merck Sharp & Dohme Llc | Nanoemulsion adjuvant compositions for human papillomavirus vaccines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0757717B1 (en) * | 1994-05-16 | 2006-05-31 | Merck & Co. Inc. | Papillomavirus vaccines |
| AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| CN1252075A (zh) | 1997-02-07 | 2000-05-03 | 麦克公司 | 合成的hiv gag基因 |
| AU734761B2 (en) * | 1997-05-27 | 2001-06-21 | Hanil Synthetic Fiber Co., Ltd. | Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| CA2339324C (en) * | 1998-08-14 | 2011-05-31 | Robert S. Lowe | Protein delivery system using human papillomavirus virus-like particles |
| AU760633B2 (en) * | 1998-08-14 | 2003-05-22 | Merck Sharp & Dohme Corp. | Process for purifying human papillomavirus virus-like particles |
| US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| ATE290013T1 (de) * | 1998-12-23 | 2005-03-15 | Merck & Co Inc | Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet |
| ATE284898T1 (de) * | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
| US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| HK1056195B (en) | 2000-07-21 | 2007-06-22 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
| US20040063188A1 (en) * | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| MXPA05010285A (es) | 2003-03-24 | 2005-11-17 | Merck & Co Inc | Expresion optimizada de hpv 31 l1 en levadura. |
-
2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh not_active IP Right Cessation
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh not_active Expired - Lifetime
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en not_active IP Right Cessation
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de not_active Expired - Lifetime
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 US US10/573,330 patent/US7250170B2/en not_active Expired - Lifetime
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en not_active Expired - Lifetime
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en not_active Ceased
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko not_active Expired - Lifetime
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja not_active Expired - Lifetime
- 2004-09-24 CA CA2539168A patent/CA2539168C/en not_active Expired - Lifetime
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt not_active IP Right Cessation
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es not_active Expired - Lifetime
-
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
-
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
-
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
-
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
-
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
-
2015
- 2015-11-30 NL NL300776C patent/NL300776I2/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I1/el unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
-
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
-
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown
-
2022
- 2022-11-30 NO NO2022051C patent/NO2022051I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011152137A5 (OSRAM) | ||
| JP2014221052A5 (OSRAM) | ||
| JP2013533745A5 (OSRAM) | ||
| CA2539168A1 (en) | Optimized expression of hpv 45 l1 in yeast | |
| CA2543928A1 (en) | Optimized expression of hpv 58 l1 in yeast | |
| RU2005132603A (ru) | Оптимизированная экспрессия hpv 31 l1 в дрожжах | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| RU2006137363A (ru) | Оптимизированная экспрессия hpv 52 l1 в дрожжах | |
| HRP20160207T1 (hr) | Prokariotska ksiloza izomeraza za konstrukciju kvasaca koji fermentiraju ksilozu | |
| JP2010533737A5 (OSRAM) | ||
| JP2015521848A5 (OSRAM) | ||
| JP2012140448A5 (OSRAM) | ||
| RU2017101446A (ru) | Получение ксилита из глюкозы при помощи рекомбинантного штамма | |
| RU2012122166A (ru) | Способы получения рекомбинантных белков с увеличенными эффективностями секреции | |
| JP2017500024A5 (OSRAM) | ||
| WO2012083445A8 (en) | Virus like particle production in plants | |
| JP2007507207A5 (OSRAM) | ||
| JP2013517773A5 (OSRAM) | ||
| CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| JP2021520836A5 (OSRAM) | ||
| CN103834582B (zh) | 一种提高衣康酸发酵产量的菌株及其构建和利用菌株生产衣康酸的方法 | |
| CN101886048B (zh) | 一种产乳酸工程菌及其构建方法和应用 | |
| CN108330145A (zh) | 重组乙肝表面抗原的生产方法 | |
| CN113151341B (zh) | 一种提高产赤藓糖醇亚罗解脂酵母耐热性的方法 | |
| CN104404057A (zh) | 一种大鲵虹彩病毒病疫苗及制备方法和应用 |